 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...27282930313233343536373839 |
- ||| Lumakras (sotorasib) / Amgen
New P1 trial, Combination therapy, Monotherapy, Metastases: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (clinicaltrials.gov) - Jul 26, 2018
P1, N=60, Not yet recruiting, Sponsor: Amgen